505.87

2.30% -12.79

Madrigal Pharmaceuticals Inc (MDGL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MDGL? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$518.66

Offen:

$518.22

24-Stunden-Volumen:

234.52K

Relative Volume:

0.68

Marktkapitalisierung:

$11.66B

Einnahmen:

$958.40M

Nettoeinkommen (Verlust:

$-288.28M

KGV:

-39.32

EPS:

-12.8641

Netto-Cashflow:

$-193.02M

1W Leistung:

-1.92%

1M Leistung:

-7.34%

6M Leistung:

+6.49%

1J Leistung:

+65.40%

1-Tages-Spanne:

$497.23

$522.01

1-Wochen-Bereich:

$497.23

$524.80

52-Wochen-Spanne:

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Firmenname

Madrigal Pharmaceuticals Inc

Sektor

Healthcare (1112)

Branche

Biotechnology (622)

Telefon

404-380-9263

Adresse

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Mitarbeiter

915

Twitter

@MadrigalPharma

Nächster Verdiensttermin

2026-05-06

Neueste SEC-Einreichungen

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDGL Madrigal Pharmaceuticals Inc	505.70	11.96B	958.40M	-288.28M	-193.02M	-12.86
VRTX Vertex Pharmaceuticals Inc	423.75	109.34B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	704.43	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	795.95	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	299.28	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	295.14	33.02B	5.36B	287.73M	924.18M	2.5229

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Eingeleitet	Barclays	Overweight
2026-01-06	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-11-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-11-03	Hochstufung	BofA Securities	Underperform → Neutral
2025-10-15	Eingeleitet	Truist	Buy
2025-09-04	Fortgesetzt	H.C. Wainwright	Buy
2025-02-28	Hochstufung	B. Riley Securities	Neutral → Buy
2025-02-27	Bestätigt	H.C. Wainwright	Buy
2024-06-28	Eingeleitet	Cantor Fitzgerald	Neutral
2024-06-11	Eingeleitet	Wolfe Research	Outperform
2024-04-22	Eingeleitet	BofA Securities	Underperform
2024-03-15	Hochstufung	B. Riley Securities	Sell → Neutral
2024-03-06	Eingeleitet	Citigroup	Buy
2024-02-26	Herabstufung	B. Riley Securities	Neutral → Sell
2022-12-20	Bestätigt	Oppenheimer	Outperform
2022-12-19	Bestätigt	H.C. Wainwright	Buy
2022-12-19	Bestätigt	Piper Sandler	Overweight
2022-12-19	Hochstufung	Raymond James	Underperform → Mkt Perform
2022-07-08	Herabstufung	B. Riley Securities	Buy → Neutral
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Fortgesetzt	Goldman	Buy
2020-11-24	Fortgesetzt	Evercore ISI	Outperform
2020-11-06	Bestätigt	H.C. Wainwright	Buy
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-06-05	Eingeleitet	BMO Capital Markets	Market Perform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-01-30	Eingeleitet	Canaccord Genuity	Buy
2020-01-09	Hochstufung	UBS	Neutral → Buy
2019-11-07	Bestätigt	H.C. Wainwright	Buy
2019-06-25	Eingeleitet	Stifel	Hold
2019-06-10	Hochstufung	B. Riley FBR	Neutral → Buy
2019-02-28	Bestätigt	H.C. Wainwright	Buy
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2019-01-23	Eingeleitet	UBS	Neutral
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-12-12	Eingeleitet	B. Riley FBR	Neutral
2018-11-19	Herabstufung	Raymond James	Mkt Perform → Underperform
2018-11-16	Hochstufung	Evercore ISI	In-line → Outperform
2018-09-04	Eingeleitet	Citigroup	Buy
2018-08-06	Herabstufung	Goldman	Buy → Neutral
2018-06-28	Eingeleitet	Raymond James	Mkt Perform

Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

11:55 AM

Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology

11:55 AM

09:24 AM

Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace

09:24 AM

08:39 AM

Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Australia

08:39 AM

08:09 AM

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline - The Manila Times

08:09 AM

May 04, 2026

Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget

May 04, 2026

May 03, 2026

MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill

May 01, 2026

Apr 30, 2026

BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $536 - Moomoo

Apr 30, 2026

Madrigal Expands Resmetirom Reach With New Post-Transplant MASH Trial - TipRanks

Apr 30, 2026

Apr 29, 2026

Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Finance Canada

Apr 29, 2026

Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Apr 29, 2026

3,876 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Moody Aldrich Partners LLC - MarketBeat

Apr 29, 2026

Madrigal to Report Q1 2026 Results May 6, Host Webcast - MyChesCo

Apr 29, 2026

Apr 28, 2026

Madrigal Pharmaceuticals Reclassifies Board Ahead of 2026 Meeting - TipRanks

Apr 28, 2026

Madrigal Pharmaceuticals | 8-K: Current report - Moomoo

Apr 28, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) reshapes Board classes ahead of 2026 meeting - Stock Titan

Apr 28, 2026

Madrigal Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo

Apr 28, 2026

[ARS] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan

Apr 28, 2026

Madrigal Pharmaceuticals | DEFA14A: Others - Moomoo

Apr 28, 2026

Madrigal Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo

Apr 28, 2026

Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish (NASDAQ:MDGL) - Seeking Alpha

Apr 28, 2026

Madrigal Grants Equity Awards to 12 New Employees - MyChesCo

Apr 28, 2026

Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN

Apr 28, 2026

Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. - BioPharma Dive

Apr 28, 2026

Pictet Asset Management Holding SA Sells 9,847 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Apr 28, 2026

Apr 27, 2026

Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN

Apr 27, 2026

Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN

Apr 27, 2026

M&T Bank Corp Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Apr 27, 2026